3078 Updated results and efficacy analysis according to epidermal growth factor receptor (EGFR) mutation subtypes and metastatic sites for the phase II trial of gefitinib in combination with carboplatin plus S1. (September 2015) - Tamiya, A.; Tamiya, M.; Shiroyama, T.; Tsuji, T.; Morishita, N.; Omachi, N.; Okamoto, N.; Hidekazu, S.; Okishio, K.; Hirashima, T.; Atagi, S.